
**Biological evaluation of medical
devices —**

**Part 23:
Tests for irritation**

*Évaluation biologique des dispositifs médicaux —
Partie 23: Essais d'irritation*





COPYRIGHT PROTECTED DOCUMENT

© ISO 2021

All rights reserved. Unless otherwise specified, or required in the context of its implementation, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
CP 401 • Ch. de Blandonnet 8
CH-1214 Vernier, Geneva
Phone: +41 22 749 01 11
Email: copyright@iso.org
Website: www.iso.org

Published in Switzerland

Contents

Page

Foreword.....	v
Introduction.....	vi
1 Scope.....	1
2 Normative references.....	1
3 Terms and definitions.....	2
4 General principles — Step-wise approach.....	3
5 Pre-test considerations.....	4
5.1 General.....	4
5.2 Types of material.....	5
5.2.1 Initial considerations.....	5
5.2.2 Ceramics, metals and alloys.....	5
5.2.3 Polymers.....	5
5.2.4 Biologically derived materials.....	5
5.3 Information on chemical composition.....	5
5.3.1 General.....	5
5.3.2 Existing data sources.....	5
6 <i>In vitro</i> irritation tests.....	6
6.1 General.....	6
6.2 <i>In vitro</i> reconstructed human epidermis model.....	6
6.2.1 Test system — Reconstructed human epidermis model.....	6
6.2.2 Principle of the method.....	6
6.2.3 Prediction model.....	7
6.3 Materials.....	8
6.3.1 Reconstructed human epidermis models — Product description.....	8
6.3.2 Preparation of medical device extracts.....	8
6.4 Methods.....	9
6.4.1 General.....	9
6.4.2 Test procedure.....	9
6.4.3 Media and end point solutions.....	10
6.4.4 Test sample and control preparation.....	10
6.5 Considerations for test performance.....	11
6.5.1 Receipt of the reconstructed human epidermis tissues.....	11
6.5.2 Preparation and pre-incubation.....	11
6.6 Application of the test sample and rinsing.....	11
6.6.1 General.....	11
6.6.2 Preparation.....	12
6.6.3 Test extract and controls exposure.....	12
6.7 MTT test for determination of RhE tissue viability after the exposure period.....	13
6.7.1 MTT incubation and Isopropanol extraction.....	13
6.7.2 Absorbance measurements.....	13
6.8 Test acceptance criteria.....	14
6.9 Data calculation steps.....	14
6.9.1 General.....	14
6.9.2 Isopropanol background control for OD in RhE assay.....	14
6.9.3 Negative DPBS or PBS treated controls.....	14
6.9.4 Positive control.....	14
6.9.5 Tested extract and VC samples (TTs).....	15
6.10 Data interpretation — Prediction model.....	15
6.11 Method documentation sheet.....	15
6.12 Test report.....	16
7 <i>In vivo</i> irritation tests.....	16
7.1 General.....	16

7.2	Animal irritation test by skin exposure	17
7.2.1	Principle	17
7.2.2	Test materials	17
7.2.3	Animals and husbandry	17
7.2.4	Test procedure	17
7.2.5	Observation of animals	19
7.2.6	Evaluation of results	19
7.2.7	Test report	21
7.3	Animal irritation test by intracutaneous (intradermal) administration	21
7.3.1	Introduction	21
7.3.2	Exclusion from test	21
7.3.3	Test sample	21
7.3.4	Animals and husbandry	22
7.3.5	Test procedure	22
7.3.6	Observation of animals	23
7.3.7	Evaluation of results	23
7.3.8	Test report	23
8	Human skin irritation test	24
8.1	Introduction	24
8.2	Initial considerations	24
	Annex A (normative) Preparation of materials for irritation testing	26
	Annex B (informative) Test method check list for <i>in vitro</i> irritation testing using reconstructed human epidermis models	28
	Annex C (informative) Example of method documentation sheet for reconstructed human epidermis models	30
	Annex D (normative) Special irritation tests	36
	Annex E (normative) Human skin irritation test	52
	Annex F (informative) Background information on irritation tests	56
	Bibliography	58

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular, the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation of the voluntary nature of standards, the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the World Trade Organization (WTO) principles in the Technical Barriers to Trade (TBT), see www.iso.org/iso/foreword.html.

This document was prepared by Technical Committee ISO/TC 194, *Biological and clinical evaluation of medical devices*, in collaboration with the European Committee for Standardization (CEN) Technical Committee CEN/TC 206, *Biological and clinical evaluation of medical devices*, in accordance with the Agreement on technical cooperation between ISO and CEN (Vienna Agreement).

A list of all parts in the ISO 10993 series can be found on the ISO website.

Any feedback or questions on this document should be directed to the user's national standards body. A complete listing of these bodies can be found at www.iso.org/members.html.

Introduction

This document assesses possible contact hazards from medical devices, which can produce irritation.

Some materials that are included in medical devices have been tested, and their skin or mucosal irritation potential has been demonstrated. Other materials and their chemical components have not been tested and can induce adverse effects when in contact with human tissue. The manufacturer is thus obliged to evaluate each device for potential adverse effects prior to marketing.

The irritation potential of a medical device or its components can be predicted either by an *in vivo* animal irritation test or by an *in vitro* irritation test if qualified for use with medical devices.

ISO 10993-2 describes animal welfare aspects for performing animal studies for the biological evaluation of medical devices thereby also emphasizing the 3R's for replacement, reduction, and refinement of animal studies. This document describes tests to determine the irritancy of medical devices, materials or their extracts either by *in vitro* tests or *in vivo* tests. *In vitro* tests have preference over *in vivo* tests when appropriately validated and providing equally relevant information to that obtained from *in vivo* tests (see ISO 10993-1 and ISO 10993-2).

Traditionally, tests in small animals have been performed prior to testing on humans to help predict human responses. More recently, *in vitro* tests as well as human tests have been added as adjuncts or alternatives. For skin irritation testing of neat chemicals *in vitro* tests were developed using reconstructed human epidermis (RhE) models^[31]. The method was adapted for detection of irritant chemicals in medical device extracts. The results of a large round robin study that tested two types of RhE models showed that these models can also be used to detect the presence of irritant chemicals extracted from polymeric materials [polyvinylchloride (PVC) and silicone] commonly used in the manufacture of medical devices^[6]. This method was found to be equally sensitive in the detection of low concentrations of some strong irritant compounds when compared to the human patch testing and intracutaneous rabbit test^[14]. Therefore, a stepwise approach for irritant testing can start with the *in vitro* RhE model.

The developed and validated RhE models are appropriate to predict skin tissue irritation response. It is recommended to explore the use of other alternative *in vitro* models to assess the irritation potential for mucosal or eye epithelial applications.

It is intended that, for regulatory submission, these studies be conducted using GLP or ISO/IEC 17025 as applicable to the respective country and comply with regulations related to animal welfare. Statistical analysis of data is recommended and can be used whenever appropriate.

This document is intended for use by professionals, appropriately qualified by training and experience, who are able to interpret its requirements and judge the outcomes of the evaluation for each medical device, taking into consideration all the factors relevant to the device, its intended use and the current knowledge of the medical device provided by review of the scientific literature and previous clinical experience.

The tests included in this document are important tools for the development of safe products, provided that they are executed and interpreted by trained personnel.

This document is based on numerous standards and guidelines, including OECD Test Guidelines (TG), U.S. Pharmacopoeia^[40] and the European Pharmacopoeia^[39]. It is intended to be the basic document for the selection and conduct of tests enabling evaluation of irritation responses relevant to the safety of medical materials and devices.

Instructions are given in normative [Annex A](#) for the preparation of materials specifically in relation to the above tests. In normative [Annex D](#) several special *in vivo* irritation tests are described for application of medical devices in areas other than skin. In addition, normative [Annex E](#) provides information for conducting human skin irritation testing.

Biological evaluation of medical devices —

Part 23: Tests for irritation

1 Scope

This document specifies the procedure for the assessment of medical devices and their constituent materials with regard to their potential to produce irritation. The tests are designed to predict and classify the irritation potential of medical devices, materials or their extracts according to ISO 10993-1 and ISO 10993-2.

This document includes:

- pre-test considerations for irritation, including *in silico* and *in vitro* methods for dermal exposure;
- details of *in vitro* and *in vivo* irritation test procedures;
- key factors for the interpretation of the results.

2 Normative references

The following documents are referred to in the text in such a way that some or all of their content constitutes requirements of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management process*

ISO 10993-2, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

ISO 10993-9, *Biological evaluation of medical devices — Part 9: Framework for identification and quantification of potential degradation products*

ISO 10993-12, *Biological evaluation of medical devices — Part 12: Sample preparation and reference materials*

ISO 10993-13, *Biological evaluation of medical devices — Part 13: Identification and quantification of degradation products from polymeric medical devices*

ISO 10993-14, *Biological evaluation of medical devices — Part 14: Identification and quantification of degradation products from ceramics*

ISO 10993-15, *Biological evaluation of medical devices — Part 15: Identification and quantification of degradation products from metals and alloys*

ISO 10993-18, *Biological evaluation of medical devices — Part 18: Chemical characterization of medical device materials within a risk management process*

ISO 14155, *Clinical investigation of medical devices for human subjects — Good clinical practice*

OECD 404, *Acute Dermal Irritation/Corrosion*

OECD 439, *In Vitro Skin Irritation: Reconstructed Human Epidermis Test Method*

3 Terms and definitions

For the purposes of this document, the following terms and definitions apply.

ISO and IEC maintain terminological databases for use in standardization at the following addresses:

- ISO Online browsing platform: available at <https://www.iso.org/obp>
- IEC Electropedia: available at <http://www.electropedia.org/>

3.1 blank

solution prepared in the same way as the sample measuring solution but so that it does not contain the analyte to be determined

[SOURCE: ISO 10136-1:1993, 3.8, modified — the term has been changed from "blank test solution" to "blank".]

3.2 dose dosage

amount of *test sample* (3.14) administered (e.g. mass, volume) expressed per unit of body weight or surface area

Note 1 to entry: The terms are often used interchangeably (more commonly dosage).

3.3 erythema

reddening of the skin or mucous membrane

3.4 eschar

scab or discoloured slough of skin

3.5 extract

liquid or suspension that results from exposing a test or control material to an extraction *vehicle* (3.16) under controlled conditions

3.6 irritant

agent that produces *irritation* (3.7)

3.7 irritation

localized non-specific inflammatory response to single, repeated or continuous application of a substance/material

Note 1 to entry: Skin irritation is a reversible reaction and is mainly characterized by local *erythema* (3.3) (redness) and swelling [*oedema* (3.9)] of the skin.

3.8 necrosis

cell death as a direct result of irreversible changes caused by injury or disease

Note 1 to entry: Tissue repair will occur either resulting in complete functional restoration or resulting in scar formation.